Source: Mallinckrodt plc & reported by http://www.prnewswire.com/
CHESTERFIELD, United Kingdom, July 28, 2016 /PRNewswire/ -- Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, today confirmed enrollment of the first patient in the company's Phase 3 clinical study to evaluate the efficacy and safety of terlipressin (for injection) in subjects with Hepatorenal Syndrome (HRS) type 1.
"Patients diagnosed with HRS type 1 typically have a very poor prognosis, and there is a significant unmet need for an approved treatment," said lead investigator Thomas D. Boyer, M.D., Director, Liver Research Institute, University of Arizona College of Medicine – Tucson. "I am excited to work with my colleagues in the hepatology community and with Mallinckrodt on this study of a potentially important therapy for U.S. patients."
Terlipressin is being investigated for the treatment of HRS type1, an acute, rare and life-threatening condition requiring hospitalization, with no currently approved therapy in the U.S. or Canada. Terlipressin is approved for use in countries outside the U.S., including several in Europe.
Read more: http://www.prnewswire.com/news-releases/first-patient-enrolled-in-mallinckrodt-phase-3-terlipressin-trial-300305910.html